

Appl. No. : 10/002,796
Filed : November 15, 2001

REMARKS

Claims 40-47 and 50-52 are pending in the present Application. Applicants respond below to the specific rejections raised by the Examiner in the final Office Action mailed May 9, 2005. For the reasons set forth below, Applicants respectfully traverse.

Rejection Under 35 U.S.C. § 101 – Utility:

The Examiner has maintained the rejection of Claims 40-47, and 50-52 as lacking a specific, substantial, and credible utility for the reasons set forth in the Office Actions mailed April 27, 2004 and August 24, 2004. The Examiner states that the asserted utilities for the PRO444 polypeptides, namely use as diagnostic markers for pericyte-associated tumors, use as reagents to identify and isolate PRO444 antagonists, and use as therapeutics to stimulate angiogenesis, are unpersuasive. The Examiner alleges that there is no evidence that PRO444 is exclusively present or expressed at altered levels in pericyte-associated tumors, and hence PRO444 cannot be used as a marker for the same. The Examiner also argues that there is no evidence that PRO444-induced activation of *c-fos* is specifically related to pericyte-associated tumors or angiogenesis.

The Examiner maintains that Dr. Gerritsen's Declaration, previously submitted with Applicants' Request for Continued Examination filed Jan 21, 2005, is insufficient to overcome the rejection under 35 U.S.C. § 101. Specifically, the Examiner asserts that Dr. Gerritsen's declaration is not backed by scientific literature showing the importance of pericytes in regulating angiogenesis or the role of *c-fos* in regulating cancer and angiogenesis. Office Action at 4. The Examiner maintains that, as Dr. Gerritsen testifies, many growth factors are known to induce *c-fos* in pericytes. Office Action at 5. The Examiner cites to Sakurai et al. and Otani et al. as supporting evidence of the various known regulators of *c-fos*. The Examiner concludes that since PRO444 is not the only regulator of *c-fos* there is thus "no specific biological function that could be particularly attributed to PRO444 with respect to its ability to activate *c-fos* expression in pericytes." Office Action at 5. The Examiner also cites to Ozerdem et al. for the proposition that the role of pericytes in the formation of tumor neovasculature varies depending on the type of tissue and tumor, and concludes that PRO444 cannot be specifically associated with the onset of cancer and angiogenesis. Finally, the Examiner argues that Coulon et al. demonstrates that

Appl. No. : 10/002,796
Filed : November 15, 2001

demonstrates that *c-fos* is activated in a range of different cell types, and therefore activation of *c-fos* in pericytes is not specific.

Applicants respectfully disagree.

Utility – Legal Standard

According to the Utility Examination Guidelines (“Utility Guidelines”), 66 Fed. Reg. 1092 (2001) an invention complies with the utility requirement of 35 U.S.C. § 101, if it has at least one asserted “specific, substantial, and credible utility” or a “well-established utility.”

Under the Utility Guidelines, a utility is “specific” when it is particular to the subject matter claimed. For example, it is generally not enough to state that a nucleic acid is useful as a diagnostic tool without also identifying the condition that is to be diagnosed. By contrast, the utility requirement is satisfied when “an applicant discloses a specific biological activity and reasonably correlates that activity to a disease condition.” M.P.E.P. § 2107.01(I).

The requirement of “substantial utility” defines a “real world” use, and derives from the Supreme Court’s holding in *Brenner v. Manson*, 383 U.S. 519, 534 (1966) stating that “The basic *quid pro quo* contemplated by the Constitution and the Congress for granting a patent monopoly is the benefit derived by the public from an invention with substantial utility.” In explaining the “substantial utility” standard, M.P.E.P. § 2107.01 cautions, however, that Office personnel must be careful not to interpret the phrase “immediate benefit to the public” or similar formulations used in certain court decisions to mean that products or services based on the claimed invention must be “currently available” to the public in order to satisfy the utility requirement. “Rather, *any reasonable use that an applicant has identified for the invention that can be viewed as providing a public benefit should be accepted as sufficient*, at least with regard to defining a ‘substantial’ utility.” (M.P.E.P. § 2107.01, emphasis added).

Indeed, the Guidelines for Examination of Applications for Compliance With the Utility Requirement, set forth in M.P.E.P. § 2107 II(B)(1) gives the following instruction to patent examiners: “If the applicant has asserted that the claimed invention is useful for any particular practical purpose ... and the assertion would be considered credible by a person of ordinary skill in the art, do not impose a rejection based on lack of utility.”

Appl. No. : 10/002,796
Filed : November 15, 2001

Utility need NOT be Proved to a Statistical Certainty – a Reasonable Correlation between the Evidence and the Asserted Utility is Sufficient

An Applicant's assertion of utility creates a presumption of utility that will be sufficient to satisfy the utility requirement of 35 U.S.C. § 101, "unless there is a reason for one skilled in the art to question the objective truth of the statement of utility or its scope." *In re Langer*, 503 F.2d 1380, 1391, 183 USPQ 288, 297 (CCPA 1974). See, also *In re Jolles*, 628 F.2d 1322, 206 USPQ 885 (CCPA 1980); *In re Irons*, 340 F.2d 974, 144 USPQ 351 (1965); *In re Sichert*, 566 F.2d 1154, 1159, 196 USPQ 209, 212-13 (CCPA 1977). Compliance with 35 U.S.C. § 101 is a question of fact. *Raytheon v. Roper*, 724 F.2d 951, 956, 220 USPQ 592, 596 (Fed. Cir. 1983) cert. denied, 469 US 835 (1984). The evidentiary standard to be used throughout *ex parte* examination in setting forth a rejection is a preponderance of the evidence, or "more likely than not" standard. *In re Oetiker*, 977 F.2d 1443, 1445, 24 USPQ2d 1443, 1444 (Fed. Cir. 1992). This is stated explicitly in the M.P.E.P.:

[T]he applicant does not have to provide evidence sufficient to establish that an asserted utility is true "beyond a reasonable doubt." **Nor must the applicant provide evidence such that it establishes an asserted utility as a matter of statistical certainty.** Instead, evidence will be sufficient if, considered as a whole, it leads a person of ordinary skill in the art to conclude that the asserted utility is more likely than not true. M.P.E.P. at § 2107.02, part VII (2004) (underline emphasis in original, bold emphasis added, internal citations omitted).

The PTO has the initial burden to offer evidence "that one of ordinary skill in the art would reasonably doubt the asserted utility." *In re Brana*, 51 F.3d 1560, 1566, 34 U.S.P.Q.2d 1436 (Fed. Cir. 1995). Only then does the burden shift to the Applicant to provide rebuttal evidence. *Id.* As stated in the M.P.E.P., such rebuttal evidence does not need to absolutely prove that the asserted utility is real. Rather, the evidence only needs to be reasonably indicative of the asserted utility.

In *Fujikawa v. Wattanasin*, 93 F.3d 1559, 39 U.S.P.Q.2d 1895 (Fed. Cir. 1996), the Court of Appeals for the Federal Circuit upheld a PTO decision that *in vitro* testing of a novel pharmaceutical compound was sufficient to establish practical utility, stating the following rule:

[T]esting is often required to establish practical utility. But the test results **need not absolutely prove** that the compound is pharmacologically active. All that is required is that the tests be "*reasonably* indicative of the desired [pharmacological] response." In other words, there must be **a sufficient**

Appl. No. : 10/002,796
Filed : November 15, 2001

correlation between the tests and an asserted pharmacological activity so as to convince those skilled in the art, **to a reasonable probability**, that the novel compound will exhibit the asserted pharmacological behavior.” *Fujikawa v. Wattanasin*, 93 F.3d 1559, 1564, 39 U.S.P.Q.2d 1895 (Fed. Cir. 1996) (internal citations omitted, bold emphasis added, italics in original).

While the *Fujikawa* case was in the context of utility for pharmaceutical compounds, the principals stated by the Court are applicable in the instant case where the asserted utility is for a diagnostic use – utility does not have to be established to an absolute certainty, rather, the evidence must convince a person of skill in the art “to a reasonable probability.” In addition, the evidence need not be direct, so long as there is a “sufficient correlation” between the tests performed and the asserted utility.

Thus, the legal standard for demonstrating utility is a relatively low hurdle. An Applicant need only provide evidence such that it is **more likely than not that a person of skill in the art would be convinced, to a reasonable probability, that the asserted utility is true**. The evidence need not be direct evidence, so long as there is a reasonable correlation between the evidence and the asserted utility. The Applicant **does not need to provide evidence such that it establishes an asserted utility as a matter of statistical certainty**.

Even assuming that the PTO has met its initial burden to offer evidence that one of ordinary skill in the art would reasonably doubt the truth of the asserted utility, Applicants assert that they have met their burden of providing rebuttal evidence such that it is more likely than not those skilled in the art, to a reasonable probability, would believe that the claimed invention is useful for the diagnosis and treatment of pericyte-associated tumors and for the stimulation of angiogenesis.

In an attempt to clarify Applicants’ argument, Applicants offer a summary of their argument and the disputes issues involved. Applicants assert they have provided reliable evidence that PRO444 stimulates *c-fos* in pericytes. Given the established role of pericytes in regulating angiogenesis, and the established role of *c-fos* in cancer and in stimulating pericytes, Applicants submit that the claimed polypeptides are useful in generating therapeutics in treating pericyte-associated tumors as well as stimulating angiogenesis.

Applicants understand the Examiner to be making the following arguments in response to Applicants’ asserted utilities:

1. The Examiner argues that there is no evidence that *c-fos* induction is associated with cancer or angiogenesis. Office Action at 4-5.

2. Citing Otani et al., Sakurai et al. and Coulon et al., the Examiner argues that several growth factors are capable of inducing *c-fos* expression, and therefore PRO444-induced *c-fos* induction is not a biological activity that can be particularly attributed to PRO444.

3. Citing Ozerdem et al., the Examiner argues that the role of pericytes in angiogenesis is not fully understood, and therefore induction of *c-fos* cannot be specifically associated with cancer or angiogenesis.

4. The Examiner argues that there is no evidence that PRO444 is present exclusively or expressed at altered levels in pericyte-associated tumors.

As detailed below, Applicants submit that the PTO has failed to meet its initial burden to offer evidence “that one of ordinary skill in the art would reasonably doubt the asserted utility.” *In re Brana*, 51 F.3d 1560, 1566, 34 U.S.P.Q.2d 1436 (Fed. Cir. 1995). The Examiner has failed to offer evidence to support the rejection of the evidence provided in the form of scientific articles and the Gerritsen declaration (i.e., that *c-fos* induction is associated with cancer or angiogenesis). To the contrary, analysis of the evidence relied upon by the Examiner establishes the association between *c-fos* induction in pericytes and angiogenesis. The fact that other known regulators of *c-fos* expression exist is irrelevant regarding whether PRO444 is a specific regulator of *c-fos*.

Applicants address each of the Examiner’s arguments in turn.

Applicants have provided evidence that c-fos induction is associated with cancer and angiogenesis

Applicants submit that the scientific literature illustrates the well-established role of *c-fos* induction in cancer and angiogenesis. For example, in Applicants’ Office Action Response mailed July 27, 2004, Applicants referenced Saez et al., a study involving *c-fos* knockout mice that demonstrated the requirement of *c-fos* for the development of malignant tumors. Saez emphasizes that their data “highlight the significance of *c-fos* for full neoplastic development.” Saez, at 730. Applicants also previously submitted a study by Marconcini et al., which establishes the importance of *c-fos* in angiogenesis. The Marconcini study demonstrated the central role of VEGF-D, a growth factor known to be induced by *c-fos*, in angiogenesis. The

Appl. No. : 10/002,796
Filed : November 15, 2001

authors note that angiogenic activity arising from *c-fos* mediated induction of VEGF “strongly suggests that VEGF-D can be a *c-fos* effector for tumor malignancy.” Marconcini et al., at 9676.

In further support of Applicants’ position, a review article by McColl et al. is submitted herewith as Exhibit 1. McColl discusses the VEGF family of proteins that are “central to angiogenesis.” McColl et al., at 463. McColl notes that “**the association between increased transcription [of VEGF-D –a regulator of angiogenesis] mediated by [c-fos] and tumorigenesis is well established.**” (McColl et al. at 471, emphasis added, internal citations omitted). In light of the above, Applicants submit that they have provided sufficient evidence of a specific activity (*c-fos* induction in pericytes) and have reasonably correlated this activity with a disease condition (tumorigenesis). These references clearly establish that one skilled in the art would believe that it is more likely than not that PRO444, an inducer of *c-fos* activity in cells having a known role in angiogenesis, (*i.e.* pericytes), is useful as an angiogenic factor. Further support is found in the three references cited by the Examiner, as discussed below.

The Arguments made by the Examiner are not Sufficient to Satisfy the PTO’s Initial Burden of Offering Evidence “that one of ordinary skill in the art would reasonably doubt the asserted utility”

As stated above, an Applicant's assertion of utility creates a presumption of utility that will be sufficient to satisfy the utility requirement of 35 U.S.C. § 101, “unless there is a reason for one skilled in the art to question the objective truth of the statement of utility or its scope.” *In re Langer*, 503 F.2d 1380, 1391, 183 USPQ 288, 297 (CCPA 1974). The evidentiary standard to be used throughout *ex parte* examination in setting forth a rejection is a preponderance of the evidence, or “more likely than not” standard. *In re Oetiker*, 977 F.2d 1443, 1445, 24 USPQ2d 1443, 1444 (Fed. Cir. 1992). This is stated explicitly in the M.P.E.P.:

[T]he applicant does not have to provide evidence sufficient to establish that an asserted utility is true “beyond a reasonable doubt.” **Nor must the applicant provide evidence such that it establishes an asserted utility as a matter of statistical certainty.** Instead, evidence will be sufficient if, considered as a whole, it leads a person of ordinary skill in the art to conclude that the asserted utility is more likely than not true. M.P.E.P. at § 2107.02, part VII (2004) (underline emphasis in original, bold emphasis added, internal citations omitted).

The PTO has the initial burden to offer evidence “that one of ordinary skill in the art would reasonably doubt the asserted utility.” *In re Brana*, 51 F.3d 1560, 1566, 34 U.S.P.Q.2d

1436 (Fed. Cir. 1995). Only then does the burden shift to the Applicant to provide rebuttal evidence. *Id.* As stated in the M.P.E.P., such rebuttal evidence does not need to absolutely prove that the asserted utility is real. Rather, the evidence only needs to be reasonably indicative of the asserted utility.

Considering the totality of the evidence of record, Applicants submit that the PTO has not met its initial burden of overcoming the presumption that the asserted utility is sufficient to satisfy the utility requirement. The evidence proffered by the Examiner to counter Applicants' own evidence not only fails to cast doubt on Applicants' asserted utilities, but it demonstrates the role of *c-fos* and pericytes in angiogenesis and neovasculature. Applicants address each reference in turn.

According to the Examiner, Otani et al. teaches *c-fos* activation in pericytes by angiotensin II and VEGF. The Examiner maintains that this evinces that there is "no specific biological function that could be particularly attributed to PRO444 with respect to its ability to activate *c-fos* expression in pericytes." Office Action at 5. As an initial matter, Applicants point out that Otani et al. teach induction of VEGF – "a potent angiogenic factor" (Otani et al., at 1192) – in retinal pericytes by *c-fos*, not induction of *c-fos* by VEGF.

Otani et al. analyzed the effect of Angiotensin II on VEGF expression in pericytes. The authors found that induction of *c-fos* in retinal pericytes (through the angiotensin II pathway) resulted in an increase in VEGF expression. Based on their results, the authors conclude that *c-fos* plays "a predominant role" in VEGF activation in pericytes. Otani et al., at 1197. As VEGF is characterized as "a potent angiogenic factor," Otani et al. demonstrates the logical correlation between *c-fos* induction in pericytes and angiogenesis.

Contrary to the Examiner's assertion, the fact that Angiotensin II is also an inducer of *c-fos* does not detract from Applicants' asserted utility. Applicants do not assert that PRO444 is the sole regulator of *c-fos* activity, or even that it is the sole regulator of *c-fos* activity in pericytes. While the Examiner "does not dispute the correctness of [Applicants'] experimental protocol," establishing that PRO444 is a specific inducer of *c-fos*, the Examiner nevertheless maintains that "there appears to be no clear physiological meaning attributed to the activation of *c-fos* by PRO444." Office Action at 6. Applicants submit that given that PRO444 can function

Appl. No. : 10/002,796
Filed : November 15, 2001

as an inducer of *c-fos* in pericytes, it is more likely than not that VEGF will in turn be activated, which is a “potent angiogenic factor.”

Similarly, the Examiner has relied on Sakurai et al. for the proposition since other known regulators of *c-fos* exist, PRO444 lacks utility. Sakurai analyzed proliferation of pericytes in response to prostaglandins. The authors found that prostaglandins stimulated *c-fos* expression in pericytes, and that the increased *c-fos* expression correlated with increased VEGF expression. The authors characterize VEGF as “a key growth factor for retinal neovascularization.” As with Otani, Sakurai et al. illustrates the logical correlation between *c-fos* induction in pericytes and angiogenesis. For the reasons discussed in connection with Otani, Applicants submit that Sakurai et al. establishes that those skilled in the art appreciate the physiological meaning attributed to the action of *c-fos* in pericytes.

The Examiner also maintains that Coulon et al. teaches that induction of *c-fos* represents a generalized, first line of cellular response. Office Action at 5. In the Office Action, the Examiner argued that the fact that *c-fos* is activated in several cell types and is not associated with a specific physiological function, indicates that there is “no scientific logic to conclude that the instant PRO444 polypeptides, as inducers of *c-fos* expression, are involved in tumorigenesis, as asserted in the instant specification.” Office Action mailed August 28, 2004, at 4. Coulon et al. teaches that calcium acts synergistically with other stimuli to activate *c-fos* transcription in fibroblast cells. As stated above, Applicants assert that the fact that other regulators of *c-fos* exist has no bearing on Applicants’ asserted utilities (e.g., as a diagnostic or therapeutic target for pericyte associated tumors, or as an angiogenic agent). Applicants have provided evidence that PRO444 stimulates *c-fos* in pericyte cells. In fact, the references cited by the Examiner are supporting evidence that those skilled in the art appreciate the connection between *c-fos* induction and angiogenesis in pericytes. Applicants submit that the teachings of Coulon *et al.* would not lead one skilled in the art to doubt that induction of *c-fos* is associated with angiogenesis in pericyte cells.

The Examiner argues that Ozerdem et al. shows that the role of pericytes in formation of tumor neovasculature is not fully understood, and therefore PRO444 lacks utility because it cannot be specifically associated with the onset of cancer or angiogenesis. Applicants respectfully disagree with the Examiner’s characterization of Ozerdem. The Examiner cites to

page 241, which reports that the relationship between pericytes and endothelial cells varies from tissue to tissue. Applicants submit that this section of Ozerdem is silent regarding the role of pericytes in the formation of neovasculature. Instead, the focus of the cited section of Ozerdem concerns the relationship between two different types of cells, *i.e.*, pericytes and endothelial cells. On the other hand, the remainder of Ozerdem confirms the association of pericytes and angiogenesis in retinal tissues. Specifically, Ozerdem notes the central role pericytes play in angiogenesis. *Id.* at 426. As a whole, the study supports Applicants' position that pericytes are linked to angiogenesis, and that one skilled in the art would more likely than not believe that induction of *c-fos* - known to have a central role in angiogenesis - would stimulate angiogenesis in pericytes.

Conclusion

The Examiner has asserted several arguments for why there is a lack of a substantial utility: (1) the Examiner alleges that there is no evidence that *c-fos* induction is associated with cancer or angiogenesis; (2) the Examiner argues that several growth factors are capable of inducing *c-fos* expression, and therefore PRO444-induced *c-fos* induction is not a biological activity that can be particularly attributed to PRO444; (3) the Examiner argues that the role of pericytes in angiogenesis is not fully understood, and therefore induction of *c-fos* cannot be specifically associated with cancer or angiogenesis; and (4) the Examiner argues that there is no evidence that PRO444 is present exclusively or expressed at altered levels in pericyte-associated tumors.

For the above reasons, the Examiner has maintained the position that the claimed polypeptides cannot be used to stimulate angiogenesis, or as a diagnostic marker or therapeutic target for pericyte-associated tumors. Applicants have addressed each of these arguments in turn.

First, the Applicants provided several references concerning the relationship between *c-fos* induction and angiogenesis and tumor neovascularization. Next, Applicants have demonstrated that the fact that PRO444 is not the exclusive *c-fos* regulator does not detract from Applicants' asserted utility. The Examiner has not offered any substantial reasoning or evidence to the contrary - the Examiner has cited to references that establish the association between *c-fos*, angiogenesis, and pericytes, supporting Applicants' asserted utility.

Appl. No. : 10/002,796
Filed : November 15, 2001

Given the totality of the evidence provided, Applicants submit that they have established a substantial, specific, and credible utility for the claimed polypeptides as angiogenic agents. According to the PTO Utility Examination Guidelines (2001), irrefutable proof of a claimed utility is not required. Rather, a specific, substantial, and credible utility requires only a “reasonable” confirmation of a real world context of use. Applicants remind the PTO that:

A small degree of utility is sufficient . . . The claimed invention must only be capable of performing some beneficial function . . . An invention does not lack utility merely because the particular embodiment disclosed in the patent lacks perfection or performs crudely . . . A commercially successful product is not required . . . Nor is it essential that the invention accomplish all its intended functions . . . or operate under all conditions . . . partial success being sufficient to demonstrate patentable utility . . . In short, **the defense of non-utility cannot be sustained without proof of total incapacity**. If an invention is only partially successful in achieving a useful result, a rejection of the claimed invention as a whole based on a lack of utility is not appropriate. M.P.E.P. at 2107.01 (underline emphasis in original, bold emphasis added, citations omitted).

Applicants submit that they have established that it is more likely than not that one of skill in the art would reasonably accept the utility for the claimed polypeptides as tools to induce angiogenesis as set forth in the specification. In view of the above, Applicants respectfully request that the PTO reconsider and withdraw the utility rejection under 35 U.S.C. §101.

Rejection Under 35 U.S.C. § 112, First Paragraph – Enablement

The Examiner has maintained the rejection of Claims 40-47, and 50-52 as not being enabled since the claimed invention is allegedly not supported by either a specific and substantial asserted utility, or a well-established utility.

Applicants submit that in the discussion of the 35 U.S.C. § 101 rejection above, Applicants have established a substantial, specific, and credible utility for the claimed polypeptides. Applicants therefore request that the Examiner reconsider and withdraw the enablement rejection to the extent that it is based on a lack of utility for the claimed polypeptides.

Rejection Under 35 U.S.C. § 112, First Paragraph – Written Description

The Examiner has maintained the rejection of Claims 40-44 under 35 U.S.C. § 112, first paragraph, as lacking adequate written description. The Examiner asserts that the specification

Appl. No. : 10/002,796
Filed : November 15, 2001

fails to provide written description for the claimed variants of SEQ ID NO:8, and that while a skilled artisan could determine if a polypeptide induces *c-fos* activation in pericytes, this limitation does not satisfy the written description requirement. The Examiner asserts that the statement that a compound is part of the invention and a reference to a potential method of isolating it is not sufficient, and that the compound itself is required.

The Legal Standard for Written Description

The well-established test for sufficiency of support under the written description requirement of 35 U.S.C. §112, first paragraph is whether the disclosure “reasonably conveys to artisan that the inventor had possession at that time of the later claimed subject matter.” *In re Kaslow*, 707 F.2d 1366, 1375, 2121 USPQ 1089, 1096 (Fed. Cir. 1983); see also *Vas-Cath, Inc. v. Mahurkar*, 935 F.2d at 1563, 19 USPQ2d at 1116 (Fed. Cir. 1991). The adequacy of written description support is a factual issue and is to be determined on a case-by-case basis. See e.g., *Vas-Cath, Inc. v. Mahurkar*, 935 F.2d at 1563, 19 USPQ2d at 1116 (Fed. Cir. 1991). The factual determination in a written description analysis depends on the nature of the invention and the amount of knowledge imparted to those skilled in the art by the disclosure. *Union Oil v. Atlantic Richfield Co.*, 208 F.3d 989, 996 (Fed. Cir. 2000).

The Current Invention is Adequately Described

As noted above, whether the Applicants were in possession of the invention as of the effective filing date of an application is a factual determination, reached by the consideration of a number of factors, including the level of knowledge and skill in the art, and the teaching provided by the specification. The inventor is not required to describe every single detail of his/her invention. An Applicant’s disclosure obligation varies according to the art to which the invention pertains. The present invention pertains to the field of recombinant DNA/protein technology. It is well-established that the level of skill in this field is very high since a representative person of skill is generally a Ph.D. scientist with several years of experience. Accordingly, the teaching imparted in the specification must be evaluated through the eyes of a highly skilled artisan as of the date the invention was made.

Applicants submit that the pending claims relating to polypeptides having 80% to 99% sequence identity to the amino acid sequence of the polypeptide of SEQ ID NO: 9 with the functional recitation “wherein said isolated polypeptide induces *c-fos* expression” are also

Appl. No. : 10/002,796
Filed : November 15, 2001

adequately described. In Example 14 of the written description training materials, the written description requirement was found to be satisfied for claims relating to polypeptides having 95% homology to a particular sequence and possessing a particular catalytic activity, even though the applicant had not made any variants. Similarly, the pending claims also have very high sequence homology to the disclosed sequences and must share the same activity *in vivo*. In Example 14, the procedures for making variants were known in the art and the disclosure taught how to test for the claimed catalytic activity. Similarly, in the instant application, it is well known in the art how to make polypeptides which have at least 80% sequence identity to SEQ ID NO: 9, and the specification discloses how to test to determine if the polypeptides induce *c-fos* expression. The facts at hand are indistinguishable from those set forth in Example 14. Like Example 14, the genus of polypeptides that have at least 80% or 99% sequence identity to the disclosed amino acid sequences will not have substantial variation since all of the variants must have the same ability to induce *c-fos*.

Furthermore, while Applicants appreciate that actions taken by the PTO in other applications are not binding with respect to the examination of the present application, Applicants note that the PTO has issued many patents containing claims to variant nucleic acids or variant proteins where the applicants did not actually make such nucleic acids or proteins. Representative patents include U.S. Patent No. 6,737,522, U.S. Patent No. 6,395,306, U.S. Patent No. 6,025,156, U.S. Patent No. 6,645,499, U.S. Patent No. 6,498,235, and U.S. Patent No. 6,730,502, which are attached hereto as Exhibits 2-7).

In conclusion, Applicants submit that they have satisfied the written description requirement for the pending claims based on the actual reduction to practice of SEQ ID NO: 9, and by describing the *c-fos* induction assay, which results in a lack of substantial variability in the species falling within the scope of the instant claims. Applicants submit that this disclosure would allow one of skill in the art to "recognize that the applicant was in possession of the necessary common attributes or features of the elements possessed by the members of the genus." Hence, Applicants respectfully request that the PTO reconsider and withdraw the written description rejection under 35 U.S.C. §112.

Appl. No. : 10/002,796
Filed : November 15, 2001

CONCLUSION

In view of the above, Applicants respectfully maintain that claims are patentable and request that they be passed to issue. Applicants invite the Examiner to call the undersigned if any remaining issues may be resolved by telephone.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: June 30, 2005

By: AnneMarie Kaiser
AnneMarie Kaiser
Registration No. 37,649
Attorney of Record
Customer No. 30,313
(619) 235-8550

1768426
061405

Molecular regulation of the VEGF family

– inducers of angiogenesis and lymphangiogenesis

BRADLEY K. McCOLL, STEVEN A. STACKER and MARC G. ACHEN

Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia

McColl BK, Stacker SA, Achen MG. Molecular regulation of the VEGF family – inducers of angiogenesis and lymphangiogenesis. *APMIS* 2004;112:463–80.

The vascular endothelial growth factor (VEGF) family of secreted glycoproteins are critical inducers of angiogenesis (growth of blood vessels) and lymphangiogenesis (growth of lymphatic vessels). These proteins are attractive therapeutic targets for blocking growth of blood vessels and lymphatics in tumors and thereby inhibiting the growth and spread of cancer – in fact, the first VEGF inhibitor has recently entered the clinic for treatment of cancer. In addition, the VEGFs are being considered for stimulation of angiogenesis in the context of ischemic disease and lymphangiogenesis for treatment of lymphedema. These therapeutic possibilities have focused great interest on the molecular regulation of VEGF family members. Much has been learned in the past five years about the mechanisms controlling the action of the VEGFs, including the importance of hypoxia, proteolysis, transcription factors and RNA splicing. An understanding of these mechanisms offers broader opportunities to manipulate expression and activity of the VEGFs for treatment of disease.

Key words: VEGF-C; VEGF-D; lymphatics; proteolysis.

Marc G. Achen, Ludwig Institute for Cancer Research, PO Box 2008, Royal Melbourne Hospital, Victoria 3050, Australia. e-mail: Marc.achen@ludwig.edu.au

Angiogenesis and lymphangiogenesis – the development of new blood vessels and lymphatics from the pre-existing vasculature, respectively – are processes with integral roles in embryonic development and numerous diseases. Angiogenesis is the better understood of the two processes, in part due to the intense research focus placed upon the field because of the significance of blood vascular development for tumor growth and ischemic disease. Angiogenesis research has progressed to the point where the first molecular therapies targeting nascent blood vessels in cancer are reaching the clinic (1–4).

A lack of molecular markers specific to the lymphatic system has been an impediment to lymphangiogenesis research until recently, when

the identification of several such markers (reviewed in (5, 6)) has led to molecular insights into lymphangiogenesis. Numerous pathologies are associated with the lymphatics, such as the metastatic spread of cancer and lymphedema, and therapeutic strategies based upon the expanding body of lymphatic knowledge are now being considered (7–9).

The development of blood vessels and lymphatics depends upon interactions between the vascular endothelium and signalling molecules derived from the serum and extracellular matrix (ECM). Among these signalling molecules, the vascular endothelial growth factor (VEGFs) family of proteins is central to angiogenesis and lymphangiogenesis. The VEGFs are dimeric endothelial cell mitogens encoded by five genes in mammals: *VEGF* (also known as *VEGF-A*), *VEGF-B*, *VEGF-C*, *VEGF-D* and placenta growth factor (*PlGF*) (10). Members of the fam-

ily are related by the characteristic VEGF homology domain (VHD), containing receptor binding sites and a conserved cystine-knot motif (10, 11). Variations in mRNA splicing generate isoforms of several of the VEGFs, adding to the complexity of the family (12–21). Recent work has advanced the understanding of the functions of the VEGFs, and uncovered some of the mechanisms by which they are regulated. This review will discuss the molecular and physiological stimuli controlling the expression and activity of the VEGF family in healthy and diseased tissues.

THE BLOOD VASCULATURE

VEGFs in embryonic development and physiological angiogenesis

VEGF. Embryonic development of the blood vascular system commences with the process of vasculogenesis, whereby endothelial cell precursors differentiate to endothelial cells and associate to form the primary vascular plexus (22, 23). Subsequent angiogenesis gives rise to a more extensive vasculature (22, 23). In the healthy adult, angiogenesis is chiefly restricted to wound healing and the female reproductive system. Postnatal neo-vascularization has been shown to make use of endothelial precursor cells from the bone marrow, which are incorporated into the nascent vessels (24, 25). New vessels are therefore not exclusively derived from the cells of pre-existing vessels.

The essential role of VEGF for embryonic vasculogenesis has been established via gene disruption studies. Disruption of a single *VEGF* allele causes embryonic lethality by embryonic day (E) 11 as a result of defective vasculogenesis, angiogenesis and large vessel formation (26, 27). Postnatal ablation of *VEGF* causes death in mice up to approximately 4 weeks of age due to defects including impaired organ development and reduced vascularisation, probably stemming from reduced angiogenesis (28). Disruption of VEGF signalling is apparently not harmful after this stage, although corpus luteum angiogenesis in the adult is VEGF dependent (29). VEGF therefore appears to have a limited role in maintaining the mature vasculature, instead impacting on those systems with an ongoing dependence upon angiogenesis.

Examination of the postnatal vascularisation of the retina reveals the mechanism whereby new vessels are stabilised and made VEGF-independent. Newly formed vessels in the retina undergo regression in the absence of VEGF (30), as a result of endothelial cell apoptosis. Temporal studies of the developing retinal vasculature reveal that formation of the vascular plexus precedes recruitment of pericytes to the new vessels, and pericyte association is crucial for stabilisation of the neo-vasculature (31). Therefore VEGF is necessary to maintain immature vessels and, without full pericyte coverage, new vessels will regress in the absence of VEGF stimulation.

The effects of VEGF are mediated by binding to VEGFR-1 and VEGFR-2, receptor tyrosine kinases expressed on the blood vascular endothelium (Fig. 1). Both VEGFR-1 and VEGFR-2 are essential for embryonic vascular development and viability, although differences in the phenotypes of mice lacking the receptors reveal distinct functions. VEGFR-2 is believed to be the principal pro-angiogenic receptor, as deletion of the *VEGFR-2* gene results in failed vasculogenesis with a lack of organised vessels and haematopoietic precursors (32). VEGFR-1 ablation causes defective assembly of endothelial cells (33), related to the development of increased numbers of hemangioblasts (34). The VEGFR-1 intracellular tyrosine kinase domain is not essential for embryonic viability (35), sug-




Fig. 1. Interaction of the VEGFs with receptors. Ligands for each receptor are listed. Where isoforms are not specified, all isoforms bind the receptor. Mature and full-length forms of VEGF-C and VEGF-D are denoted "m" and "f", respectively. The proposed function is listed below each receptor. The role of VEGFR-1 in angiogenesis is uncertain.

gesting that VEGFR-1 may be a negative regulator of VEGF activity.

Several isoforms of VEGF exist, generated by alternative mRNA splicing (12–16). The smallest isoform, VEGF₁₂₁ is freely soluble, whereas VEGF₁₈₉ and VEGF₂₀₆ are completely bound to the ECM (36). The predominant isoform, VEGF₁₆₅, exists as both soluble and ECM-bound forms. Emerging data show specific functions for the VEGF isoforms (37), possibly relating to the isoform-specific binding of VEGF to a second class of receptors, the Neuropilins. Neuropilin-1 (NRP-1) and Neuropilin-2 (NRP-2) are cell surface receptors associated with neuronal guidance (38). VEGF₁₆₅ binds both NRP-1 and NRP-2, but VEGF₁₄₅ binds NRP-2 only (39–41). Overexpression of the *NRP-1* gene is lethal at the embryonic stage, resulting in excessive capillary and blood vessel formation, thinning of the walls of the heart, and defects in other systems (42). Likewise, deletion of *NRP-1* causes death due to defects in embryonic vascularisation, although at later stages than those seen in VEGFR-2 deficient mice (43). *NRP-2* is not required for viability, but disruption of both *NRP-1* and *NRP-2* genes results in embryonic death due to severe vascular abnormalities, similar to those of VEGF or VEGFR-2 deficient mice (44). Furthermore, co-expression of NRP-1 with VEGFR-2 suggests that NRP-1 enhances VEGF binding to VEGFR-2 (40). NRP-1 may therefore function in concert with VEGFR-2 as a VEGF co-receptor during angiogenesis.

Despite the function of VEGF as a primary inducer of angiogenesis, some studies of VEGF-mediated initiation of blood vessel growth suggest that this growth factor alone is insufficient to establish mature vessels. Studies in which VEGF is elevated, in muscle from engineered myoblasts (45), transgenically in the skin (46) or systemically using adenoviral vectors (47) resulted in vascular leakage with associated inflammation. It seems that additional signalling molecules, most notably the Angiopoietins, their receptors the Ties, and the Ephrins are also necessary to give rise to fully functional vessels (23, 48–50).

VEGF-B. Although closely related to VEGF (19, 51), the physiological function of VEGF-B is less clear. Alternative RNA splicing generates

two isoforms of VEGF-B, VEGF-B₁₆₇ and VEGF-B₁₈₆ (20), the larger of which is the predominant mRNA species (52). Both isoforms are ligands for VEGFR-1 and NRP-1 (Fig. 1), although VEGF-B₁₈₆ requires proteolytic cleavage of the C-terminal region for binding to NRP-1 (53) (Fig. 2). Neither isoform binds VEGFR-2 or VEGFR-3 (53, 54). VEGF-B induces a mitogenic response in endothelial cells *in vitro* (51), and expression of VEGF-B in the embryonic heart and adult cardiac and skeletal muscle suggests a role in vascularisation of the musculature (51). However, VEGF-B does not appear to be strongly angiogenic as indicated by adenoviral delivery to periadventitial tissue (55) or hindlimb skeletal muscle (56). Unlike VEGF, mice lacking VEGF-B are viable, but suffer from smaller hearts, abnormal coronary vasculature and defective recovery from cardiac ischemia (57). Certain VEGF isoforms are also required for development of the heart (37), and coexpression studies have shown that VEGF and VEGF-B can form heterodimers (51). Together these data indicate a role for VEGF-B in cardiac development, possibly in cooperation with VEGF.

PlGF. PlGF is expressed in the placenta throughout pregnancy, and also in the heart, lung, brain and skeletal muscle (58, 59). Alternative splicing of the human primary transcript generates three isoforms: PlGF₁₃₁ (PlGF-1), PlGF₁₅₂ (PlGF-2) and PlGF₂₀₃ (PlGF-3) (17, 18). Like VEGF-B, PlGF is a ligand for VEGFR-1 but not VEGFR-2 (58, 60), and PlGF-2 is able to bind NRP-1 and NRP-2 (61, 62) (Fig. 1). PlGF homodimers are poor inducers of angiogenesis *in vivo*, and only provoke a weak mitogenic response from endothelial cells (60, 63). VEGF can form heterodimers




Fig. 2. Proteolytic activation of the VEGFs. Shading represents regions of the protein removed by proteolysis. Functional outcomes of proteolysis are listed below each growth factor.

with PlGF(63), although conflicting evidence exists as to the capacity of such heterodimers to induce angiogenesis (63, 64). Deletion of the *PlGF* gene in mice does not cause significant defects in vascular development (65), although overexpression of *PlGF* in the skin results in increased vessel formation and permeability (66), demonstrating a pro-angiogenic role for the growth factor. PlGF stimulates angiogenesis as well as migration and proliferation of endothelial cells *in vitro* in a manner dependent upon VEGF and VEGFR-1 (65). A model has been suggested to explain these observations (65), in which PlGF binding to VEGFR-1 signals for angiogenesis, whereas VEGF binding does not. PlGF binding to VEGFR-1 would displace VEGF from the receptor, increasing the amount of soluble VEGF available for pro-angiogenic binding to VEGFR-2. The VEGFR-1 tyrosine kinase domain is not essential for embryonic vascular development (35), indicating that VEGFR-1 acts as a non-signalling receptor which is consistent with the normal vascular development observed in PlGF deficient embryos (65).

In vivo studies of ischemia have shown that PlGF treatment stimulates arteriogenesis, the enlargement of pre-existing arterioles (67, 68). Ablation of the *PlGF* gene inhibits this process, a phenotype which can be rescued by bone marrow transplantation (69). PlGF is capable of stimulating migration and tissue factor production in monocytes (70), and PlGF treatment results in elevated extravasation of macrophages (68). These lines of evidence concur with the observed contribution of bone marrow derived endothelial cell precursors to vessel formation (25), indicating a role for haematopoietic cells in angiogenesis, in response to stimulation by PlGF.

Pathological angiogenesis

Aberrant or insufficient vascularisation of tissues is a feature of several pathologies, including arthritis, atherosclerosis, diabetic retinopathy and tumor growth. In the case of cancer, access to the blood supply and the nutrients therein is a necessary precursor for significant tumor growth, making tumor angiogenesis a target for emerging therapeutics (71–74). In contrast to developmental angiogenesis, tumor angiogenesis results in irregularly shaped, convoluted vessels that exhibit disorganised or even

reversed blood flow (73). Furthermore, tumor derived vasculature is often leaky, a characteristic of immature blood vessels (75). Tumor angiogenesis may incorporate cancer cells into the wall of the developing vessel (76), and tumor models have been reported in which vessel growth involves the recruitment of circulating endothelial precursor cells, suggesting that new vessels are not solely derived from pre-existing vasculature (25). It has also been hypothesised that some tumor cell types may form vessel-like structures independently of the endothelium (77). Tumor angiogenesis therefore appears to be a somewhat chaotic process, in which normal signalling molecules are co-opted in a disorganised manner to provide the tumor with improved access to the blood supply (73).

The evidence for VEGF as a primary inducer of tumor angiogenesis is extensive. Animal xenograft models of cancer in which the *VEGF* gene has been disrupted, or VEGF signalling blocked, show drastically reduced growth of tumors, demonstrating the significance of VEGF in tumor growth (27, 78–80). Surveys of human cancers reveal significant elevation of VEGF expression in the majority of tumors examined, including those from the lung, breast, gastrointestinal tract, ovary and colon (81–85). Expression of VEGF correlates with increased tumor vascularisation and poor patient prognosis (81, 86, 87), suggesting VEGF as a therapeutic target, and leading to the development of therapies based upon inhibition of VEGF activity. The approval of the US Food and Drug Administration of Avastin™, a neutralizing antineutralizing antibody to VEGF, for treatment of metastatic colorectal cancer has focussed great interest on the field of anti-angiogenesis as an approach to cancer therapy (1, 4).

PlGF may be associated with pathological angiogenesis as demonstrated by decreased vascularisation of tumor models lacking PlGF (65), although expression of PlGF has been reported to be variable in human cancers (88–90). Inhibition of the PlGF receptor VEGFR-1 suggests a role for PlGF in tumor angiogenesis as well as arthritis and atherosclerosis (67), possibly through synergistic effects with VEGF (reviewed in (91)). Examination of VEGF-B in tumors reveals little conclusive data to indicate a substantial role for VEGF-B in tumor progression (92, 93), although isoform specific vari-

ation of VEGF-B expression in tumors has been reported (52).

Molecular regulation of angiogenic VEGFs *VEGF*

Hypoxia. Cellular growth and proliferation beyond the dimensions through which oxygen can readily diffuse results in reduced oxygen tension in the tissue. Within the cell, a number of metabolic alterations occur in response to hypoxia, including the synthesis of pro-angiogenic growth factors targeting the vascular endothelium, most notably VEGF (94). Hypoxia has been demonstrated to be a major regulator of VEGF both *in vitro* and *in vivo* (95–97) (Table 1), and VEGF mRNA is elevated in ischemic tumor cells adjacent to areas of necrosis (98). These observations have led to efforts to identify inhibitors of the hypoxic response as novel cancer therapeutics (99).

The cellular response to hypoxia is mediated by the hypoxia-inducible transcription factor (HIF-1), a heterodimeric protein which binds to hypoxia response elements (HRE) in the promoter/regulatory regions of hypoxia-inducible genes, including the *VEGF* gene, and initiates transcription by recruitment of transcriptional activators such as CREB/p300 (100). Under normoxic conditions, the α subunit of HIF-1 is degraded via the ubiquitin-proteasome pathway, preventing formation of active HIF-1 (for review of HIF-1 regulation see (101)). The ubiquitination step is mediated by the von Hippel-Lindau (VHL) protein (102), which recognises hydroxylated proline residues in HIF-1 α (101). Proline hydroxylation of HIF-1 α is cata-

lysed by a family of three prolyl hydroxylases utilising molecular oxygen as a substrate (103). Studies of recombinant prolyl hydroxylases demonstrate that the affinity of these enzymes for oxygen is such that their activity is reduced at oxygen concentrations observed in hypoxic tissues (104), leading to reduced ubiquitination-degradation of HIF-1 α . Hydroxylation of an asparagine residue also regulates the activity of the C-terminal transactivation domain of HIF-1 α by blocking interactions with the transcriptional activator p300 (105). As with the prolyl hydroxylases, activity of the enzyme responsible is dependent upon oxygen concentration at physiological levels (106, 107). Hydroxylation of HIF-1 α therefore acts as a hypoxia sensitive switch linking local oxygen concentrations to the stability and activity of the transcription factor, and hence to VEGF expression.

Genes associated with transformation. Numerous genes associated with tumorigenic transformation are also involved with regulation of VEGF expression (Table 1). Examination of the *VEGF* gene promoter region reveals the presence of consensus AP-1 sequences, sites recognised by the c-fos family of transcription factors (15). The c-fos family are proto-oncogenes which activate transcription by binding to AP-1 sites in transcriptional promoters (for review see (108)). Since fos is upregulated by treatment with phorbol esters and various growth factors, VEGF expression could also be elevated in response to these stimuli, as is indeed the case (15, 109–112).

The *ras* oncogene is another logical candidate to activate VEGF expression, as *ras* activity is a

TABLE 1. *Regulators of the VEGFs. Arrows indicate positive (↑) or negative (↓) stimuli*

VEGF	PlGF	VEGF-B	VEGF-C	VEGF-D
Regulation of transcription				
↑ Hypoxia				
↑ Inflammatory mediators/COX-2	↑ Hypoxia ↑ FoxD1 transcription factor		↑ Inflammatory mediators/COX-2	↑ AP-1 transcription factors ↑ Cell-cell contact
↑ AP-1 transcription factors				
↑ Mutant <i>ras</i>				
↑ Mutant p53				
Post-transcriptional regulation				
↑ Proteolysis (release from ECM)		↑ Proteolysis	↑ Proteolysis	↑ Proteolysis ↓ Cytosolic β -catenin

component of the signal transduction pathway linking extracellular stimuli to AP-1 mediated activation of transcription (108). Oncogenic, activated ras stimulates VEGF expression in cell lines (113, 114), and ras activity is associated with VEGF expression, tumorigenicity and angiogenesis in mouse models of cancer (115, 116). Therefore oncogenic ras may play a role in stimulating angiogenesis as well as driving proliferation of tumor cells in cancer.

A transcriptionally inactive mutant of the tumor suppressor p53 causes elevated VEGF expression (117), and wild-type p53 represses VEGF transcription (118). Deletion of the p53 gene in tumor cells results in enhanced vascularisation and tumor growth, and p53-deficient cells show increased induction of VEGF under hypoxic conditions (119). The p53 protein promotes ubiquitination and degradation of HIF-1 α (119), hence VEGF expression is enhanced by HIF-1 in the absence of p53. In addition to upregulating VEGF, mutation of p53 may confer resistance to antiangiogenic therapies, as hypoxia-induced apoptosis is p53 dependent. A p53 mutant tumor model has shown reduced responsiveness to therapies targeting the vasculature (120), demonstrating that p53 status may be a factor when considering anti-VEGF therapies.

RNA splicing isoforms and proteolysis. VEGF exists as a number of isoforms derived from mRNA splice variants (12, 14–16). The isoforms differ at the C terminus, with the larger variants exhibiting substantial affinity for heparin (36). The smallest isoform, VEGF₁₂₁, does not bind heparin and is freely soluble upon secretion, whereas the higher molecular weight isoforms bind to the cell surface/extracellular matrix (ECM) (36, 121). VEGF isoforms sequestered in this way can be released from the ECM by the action of heparinase or the fibrinolytic serine protease plasmin, giving rise to soluble, biologically active molecules (36, 121) (Fig. 2). It has been proposed that the ECM-bound forms of VEGF represent a pool of available growth factor, which can be activated in the course of tissue remodelling in conjunction with the degradation of ECM components necessary for neovascularisation (121).

Inflammatory cytokines and cyclooxygenase-2 (COX-2). The inflammatory condition rheu-

matoid arthritis is characterised by proliferation of the synovium, including large numbers of blood vessels, and invasion of the adjacent cartilage. Angiogenesis is a significant component of this process, believed to be driven by local production of angiogenic growth factors (91). Inflammatory mediators such as IL-1 α , IL-1 β , TGF- β and prostaglandin E2 (PGE2) induce VEGF expression in a number of cell types, including umbilical vein endothelial cells, smooth muscle cells and synovial fibroblasts (111, 122–125). VEGF is therefore a potential target for intervention in inflammatory disease. Furthermore, the enzyme COX-2 is an inducible component of the inflammatory prostaglandin synthesis pathway, and is upregulated in many human cancers (126). Inhibitors of the enzyme demonstrate anti-angiogenic activity in animal models of cancer, suggesting that COX-2 activity may be a target for therapies acting indirectly on VEGF (127, 128).

PlGF and VEGF-B

Like VEGF, PlGF is also induced by hypoxia (129), and recent work has shown *PlGF* expression to be activated by FoxD1, a member of the Forkhead/Winged Helix family of transcription factors associated with branching of the ureteric bud in the kidney (130). *PlGF*-null mice have not been reported to develop renal defects, indicating either a non-essential or redundant role for PlGF in the kidney. In addition, PlGF is upregulated in keratinocytes during wound healing (65, 131). The three human isoforms of PlGF differ in their affinities for the ECM, with PlGF-2 incorporating a sequence of 21 amino acids necessary for binding to heparin (17, 132). VEGF and PlGF are therefore both regulated according to tissue oxygenation and matrix interactions, demonstrating the interplay between vascular development and the ECM.

VEGF-B does not respond to hypoxia, Ras oncoprotein or several other stimuli known to regulate other VEGF family members (112, 133, 134), and the mechanisms whereby *VEGF-B* gene expression is regulated remain unclear.

THE LYMPHATIC VASCULATURE

The lymphatic vasculature is composed of a network of blind-ended, thin-walled vessels and

capillaries lined by a continuous layer of endothelial cells (135). Extravasated fluid and solutes from the extracellular spaces are collected by the initial lymphatics, then passed through a network of progressively larger lymphatic vessels, finally returning to the blood circulation via the thoracic duct (136). In addition, the lymphatic system is a major site of immune surveillance as stimulated dendritic cells migrate to the lymph nodes where foreign antigens are presented to lymphocytes (137).

Embryonic development and physiological lymphangiogenesis

The lymphatic vessels develop subsequent to the formation of the blood vasculature, leading to the suggestion that they are derived from the blood vessels (138). Recent advances in the understanding of lymphatic development have shown that expression of the homeobox transcription factor Prox-1 by a population of endothelial cells in the cardinal vein during embryogenesis is a defining characteristic of differentiation to the lymphatic phenotype (139, 140). Subsequent budding and sprouting of the Prox-1 positive cells gives rise to the lymphatic vasculature (for review see (141)).

Two members of the VEGF family, VEGF-C and VEGF-D, have been shown to act as lymphangiogenic growth factors (142, 143). Expression of either growth factor in the skin of transgenic mice results in lymphatic hyperplasia without altering the blood vasculature (143, 144). Disruption of the *VEGF-C* gene demonstrates that the growth factor is indispensable for embryonic lymphangiogenesis (145). Embryos carrying a homozygous deletion of *VEGF-C* are not viable, and fail to form the initial lymph sacs which generate the lymphatic vasculature. Prox-1 expression was detected in endothelial cells of VEGF-C deficient embryos, but the Prox-1 positive cells failed to migrate from the cardinal vein (145), indicating that VEGF-C is required for migration of the endothelial cells which go on to form the lymphatic system. *VEGF-C* exhibits a gene dosage effect as mice carrying only one functional *VEGF-C* allele are prone to lymphedema (145). The role of VEGF-D during embryonic development is unknown.

In the human, VEGF-C and VEGF-D are ligands for VEGFR-2 and the related receptor

tyrosine kinase VEGFR-3 (146, 147), although mouse VEGF-D binds only VEGFR-3 (148). In the early embryo VEGFR-3 is broadly expressed on the endothelium, but in time becomes restricted to the lymphatic endothelium (149), leading to the suggestion that VEGFR-3 signals for lymphangiogenesis. Functional studies support this hypothesis, demonstrating that VEGFR-3 transduces mitogenic and migratory signals in lymphatic endothelial cells, and stimulation of the receptor blocks apoptosis induced by serum starvation (150). Furthermore, expression in the skin of a mutant form of VEGF-C specific for VEGFR-3 causes lymphatic hyperplasia without altering blood vessel structure (143), and disruption of VEGFR-3 signalling in the same model blocks development of the lymphatic phenotype (143). VEGFR-3 is therefore a major transducer of lymphangiogenic signalling in the adult. In addition, deletion of the *VEGFR-3* gene results in embryonic death due to defective remodelling of the large blood vessels (151). VEGFR-3 therefore has a role in embryonic vascular development prior to the emergence of the lymphatics.

VEGF-C has also been shown to bind to NRP-2 (152), and deletion of the *NRP-2* gene impairs formation of the small lymphatics (153), leading to the hypothesis that NRP-2 may act as a co-receptor for VEGFR-3, in a fashion analogous to NRP-1 acting as a co-receptor for VEGFR-2 (Fig. 1).

Examination of VEGF-C and VEGF-D function in a number of assays has also shown an angiogenic activity for the growth factors (154–158), presumably via activation of VEGFR-2. Gene delivery experiments using adenoviruses expressing VEGFs show induction of angiogenesis by VEGF-C and VEGF-D *in vivo* (55, 56). Although the physiological significance of VEGF-C and VEGF-D in angiogenesis is unclear the promising results achieved so far with gene delivery approaches suggest a role for the factors in therapy for ischemic disease.

Pathological lymphangiogenesis and lymphatic dysfunction

Cancer. Given the propensity for numerous types of cancer to metastasize via the lymphatic system, it has been proposed that tumors may stimulate lymphangiogenesis in a manner analogous to tumor angiogenesis, thereby promot-

ing lymphogenous metastasis (6, 159). The production of lymphangiogenic growth factors is believed to stimulate lymphatic vessel development in the region of the tumor, enabling cancer cells to gain access to the lymphatic vasculature.

A number of animal models have been utilised to examine the potential of VEGF-C and VEGF-D to promote lymphatic metastasis. Studies in which VEGF-C or VEGF-D were expressed in transplanted tumor cells or transgenic tumor models have demonstrated that these growth factors promote tumor lymphangiogenesis and lymphatic metastasis (160–164). Furthermore, clinicopathological studies of these lymphangiogenic growth factors in cancer reveal that, in many instances, expression of VEGF-C or VEGF-D does indeed correlate with the capacity of a tumor to metastasize (165–170). Analysis of xenograft tumor models has revealed that VEGF-C and VEGF-D can also drive tumor angiogenesis and accelerate solid tumor growth (158, 164), potentially as a result of VEGFR-2 activation. For a complete discussion of VEGF-C and VEGF-D and tumor lymphangiogenesis, see Stacker *et al.*, this issue.

Lymphedema. A spectrum of pathologies exists stemming from inadequate lymphatic function (for review of disorders of the lymphatic system see (135, 171)). Although sharing the common feature of fluid accumulation in tissues as a result of inadequate lymphatic drainage (lymphedema), the underlying causes may be either familial or acquired. Specific genetic lesions have been identified in a few instances of inherited lymphedema, providing insights into lymphangiogenesis. Specifically, mutations in the *VEGFR-3* gene have been identified in a number of cases (172, 173), and the forkhead transcription factor *FOXC2* is also implicated in congenital lymphedema (174). Acquired lymphedema can be the result of infection (commonly filariasis) or lymph node resection and radiation treatment of cancer. Regardless of the cause, current treatments for lymphedema are targeted towards alleviating symptoms rather than treating the underlying causes (171). A better understanding of the molecular control of lymphangiogenesis offers the potential to develop novel treatments for this painful and disfiguring condition based on stimulating lymphatic

development to enhance or restore lymphatic function (7, 8).

Molecular regulation of lymphangiogenic VEGFs

Proteolytic activation of VEGF-C and VEGF-D. VEGF-C and VEGF-D are both synthesised as proproteins, with the central receptor binding VEGF homology domain (VHD) flanked by N- and C-terminal propeptides (146, 147). During biosynthesis the propeptides are cleaved off, yielding the mature VHD (175, 176). As a consequence of proteolysis VEGF-C acquires the capacity to bind to VEGFR-2 (175) and a recombinant mature form of VEGF-D shows an approximately 290-fold greater affinity for VEGFR-2 than unprocessed VEGF-D (176). Full-length forms of both growth factors bind to VEGFR-3, but do so with greater affinity after proteolytic maturation (175, 176). In support of these observations, mutation of one of the sites of proteolytic cleavage in VEGF-C has been shown to reduce lymphangiogenesis and angiogenesis induced by VEGF-C in a mouse tumor model (177).

The capacity of the mature forms of VEGF-C and VEGF-D to act as ligands for VEGFR-2 explains how these proteins stimulate angiogenesis in addition to lymphangiogenesis (156–158, 164). The proteolysis-dependent binding to VEGFR-2 may represent a mechanism whereby the angiogenic activity of VEGF-C and VEGF-D is activated.

The marked effect of the proteolytic activation of VEGF-C and VEGF-D on their affinity for VEGFR-2 and VEGFR-3 indicates that the enzymes carrying out this processing are important regulators of lymphangiogenesis and angiogenesis. Treatment of VEGF-C and VEGF-D with the fibrinolytic serine protease plasmin was recently shown to generate fully processed, mature forms of the VHD with greatly enhanced capacities to activate both VEGFR-2 and VEGFR-3 (178). Since plasmin can also release ECM-bound VEGF, this enzyme is capable of activating both angiogenic (36) and lymphangiogenic growth factors (Fig. 2). These findings suggest that plasmin is a master regulatory molecule that co-ordinates lymphangiogenesis, angiogenesis and fibrinolysis during wound healing.

Some members of the furin/proprotein con-

vertase (PC) family of proteases have also been shown to partially activate VEGF-C (177). The PCs are a family of ubiquitously expressed proteases capable of activating a range of precursor proteins by cleavage downstream of dibasic residues. Substrates for the PCs include numerous growth factors, zymogens, receptors and viral proteins (for review of PC function see (179, 180)). The PCs furin, PC5 and PC7 are able to cleave VEGF-C at the C-terminal site of proteolysis, thereby cleaving the C-terminal propeptide from the VHD (177). However, it is not known if PCs cleave the N-terminal propeptide from the VHD, nor if they process VEGF-D.

These observations suggest a model in which VEGF-C and VEGF-D may be activated in various biological contexts. Firstly, regulated expression of PCs could activate VEGF-C and VEGF-D during embryogenesis, when plasmin is unlikely to play a role (note that mice deficient for plasminogen, the plasmin precursor, are viable and have not been reported to suffer lymphedema (181)). Plasmin could activate VEGF-C and VEGF-D from a pool of inactive full-length molecules in response to tissue damage in adults. It is known that both VEGF-C and VEGF-D are localised in vascular smooth muscle in adult human tissues (182, 183). Local activation of these molecules in response to tissue damage and plasmin production could represent a mechanism for stimulating rapid vessel repair during wound healing. In addition, activation of VEGF-C and VEGF-D by plasmin may be associated with tumor lymphangiogenesis, given that plasminogen deficient mice show delayed formation of lymph node metastases when inoculated with Lewis lung carcinoma cells (184). Upregulation of VEGFR-2 and VEGFR-3 on blood vessels during wound healing and tumor angiogenesis (185) may facilitate the development of new vessels.

Induction of VEGF-C expression by inflammatory cytokines. Interleukin-1 (IL-1) and Tumor Necrosis Factor- α (TNF- α) stimulate VEGF-C expression in human lung fibroblasts and human umbilical vein endothelial cells (HUVEC) (186). In conjunction with inflammation-induced VEGF expression and angiogenesis, expression of VEGF-C and consequent lymphangiogenesis may have a role in maintaining fluid balance in the inflamed tissue. Also, an immune

response at the site of inflammation may depend upon increased lymphatic function in the affected area. It therefore seems logical that inflammatory mediators can induce expression of a lymphangiogenic growth factor such as VEGF-C.

VEGF-C and COX-2. The association of VEGF-C with the inflammatory response extends to COX-2. Recent work has shown COX-2 to be capable of upregulating VEGF-C expression in human lung adenocarcinoma cells (187). In addition to VEGF-C, COX-2 activity and some prostaglandins produced by COX-2 (188) also elevate angiopoietin-2, another protein required for lymphangiogenesis (189). COX-2 is therefore an inducer of two proteins integral to lymphangiogenesis. This relationship has significant implications for tumor lymphangiogenesis and metastasis, given the earlier observation that elevated COX-2 expression may be associated with lymph node metastasis from adenocarcinoma of the lung (190). COX-2 may therefore be a major inducer of angiogenic and lymphangiogenic proteins, and a potential target for anti-metastatic therapies based upon existing anti-inflammatory compounds.

VEGF-D induction by fos. The mouse homologue of VEGF-D was originally identified as a novel c-fos responsive gene (191), and subsequent investigation of the X-linked human VEGF-D gene (192) revealed a canonical AP-1 binding site in the transcriptional promoter (192, 193). It has been reported that VEGF-D levels are high in glioblastoma multiforme (GBM), yet levels of c-fos are very low in this tumor (194). However, the fos-related antigen-1 (fra-1), another AP-1 transcription factor, is elevated in GBM and induces VEGF-D expression (194). Therefore, the AP-1 transcriptional activation pathway appears to be a regulator of VEGF-D expression. Although the significance of this relationship in healthy physiology is unclear, the association between increased transcription mediated by AP-1 and tumorigenesis is well established (108). Therefore, elevated AP-1 activity may lead not only to neoplasia, but also to tumor angiogenesis and lymphangiogenesis via elevated VEGF-D expression.

VEGF-D and cell-cell contact. The cadherins are a family of calcium-dependent cell surface pro-

teins which mediate cell-cell adhesion through homotypic binding with their counterparts on adjacent cells (195). VEGF-D expression has been shown to be enhanced by cadherin-11 *in vitro* whereas inhibition of cadherin-11 expression reduces VEGF-D induction (196). In addition, VEGF-D mRNA stability is downregulated by cytosolic β -catenin (197). β -catenin exists either as a structural protein at the cell membrane in a complex with the cadherins, or in the cytoplasm. Repression by cytosolic β -catenin and upregulation in response to cadherin-11 implies that VEGF-D expression is dependent upon stable cellular interactions with the surrounding environment, and may have implications for the secretion of lymphangiogenic growth factors by migrating cells.

CONCLUDING REMARKS

Numerous members of the VEGF family share common mechanisms of regulation. Regulating the angiogenic and lymphangiogenic activities of the VEGFs via common pathways may allow coordinated development of the lymphatic and blood vasculature, necessary for fluid homeostasis.

The existence of multiple protein isoforms generated by variations in RNA splicing has been reported for all mammalian VEGFs except VEGF-C. In the case of VEGF (14–16), VEGF-B (19, 20) and PlGF (17, 18) the generation of isoforms with different affinities for heparin and the ECM/cell surface regulates the biological distribution of these molecules. However, the significance of the two isoforms of mouse VEGF-D (21), that differ in the C-terminal peptide, is as yet unknown.

Proteolysis regulates several VEGFs (Fig. 2), and significantly influences receptor affinity of one isoform of VEGF-B (53), and receptor affinity and specificity of VEGF-C (175) and VEGF-D (176). Proteolysis also modulates VEGF activity, by releasing ECM-bound forms of VEGF (36). The findings that plasmin can activate both VEGF-C and VEGF-D (178), in addition to releasing VEGF from the ECM (36), indicate the potential importance of this protease for co-ordinating angiogenesis, lymphangiogenesis and fibrinolysis in wound healing.

Hypoxia is a critical stimulus for the angio-

genic factors VEGF (95–98) and PlGF (129); however, there is no compelling evidence that it drives the expression of the lymphangiogenic growth factors VEGF-C and VEGF-D. This seems logical given that modulation of tissue oxygenation is not a direct function of the lymphatic vasculature.

The identification of the VEGFs as inducers of angiogenesis and lymphangiogenesis has led to new therapeutic possibilities for diseases associated with vascular function. These include stimulation of these processes using recombinant proteins or gene delivery systems to treat ischemic disease and lymphedema. Additionally, pathological angiogenesis and lymphangiogenesis in solid tumors could be blocked by inhibitors of these growth factors, such as monoclonal antibodies and soluble receptors. However, as our understanding of the mechanisms regulating the VEGFs becomes more extensive there will be opportunities to manipulate the stimuli that influence the production or activity of these growth factors. For example, it may prove clinically attractive to inhibit the proteases that activate the lymphangiogenic growth factors in order to block formation of tumor lymphatics and the resultant lymphogenous metastasis. Likewise, inhibitors of the HIF-1 hypoxia response pathway may be of benefit to block production of VEGF and resultant tumor angiogenesis (99). Future advances in our understanding of the biological regulation of the VEGFs will reveal more potential approaches for manipulating angiogenesis and lymphangiogenesis in the clinic.

This work was supported by the National Health and Medical Research Council of Australia (NH&MRC). BKM is supported by a Melbourne Research Scholarship from the University of Melbourne, SAS by a Senior Research Fellowship from the Pharmacia Foundation, and MGA by a Senior Research Fellowship from the NH&MRC. We thank Tony Burgess for helpful comments.

REFERENCES

1. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. *N Engl J Med* 2003;349:427–34.

2. Fiedler W, Mesters R, Tinnefeld H, Loges S, Staib P, Duhrsen U, et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. *Blood* 2004;102:2763-67.
3. Willett CG, Boucher Y, di Tomaso E, Duda EG, Munn LL, Tong RT et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivasular effects in human rectal cancer. *Nat Med* 2004;10:145-7.
4. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. *J Clin Oncol* 2003;21:60-5.
5. Stacker SA, Baldwin ME, Achen MG. The role of tumor lymphangiogenesis in metastatic spread. *FASEB J* 2002;16:922-34.
6. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. *Nat Rev Cancer* 2002;2:573-83.
7. Szuba A, Skobe M, Karkkainen MJ, Shin WS, Beynet DP, Rockson NB, et al. Therapeutic lymphangiogenesis with human recombinant VEGF-C. *FASEB J* 2002;16:1985-7.
8. Saaristo A, Veikkola T, Tammela T, Enholm B, Karkkainen MJ, Pajusola K, et al. Lymphangiogenic gene therapy with minimal blood vascular side effects. *J Exp Med* 2002;196:719-30.
9. Yoon Y, Murayama T, Gravereaux E, Tkebuchava T, Silver M, Curry C et al. VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. *J Clin Invest* 2003;111:717-25.
10. Achen MG, Stacker SA. The vascular endothelial growth factor family; proteins which guide the development of the vasculature. *Int J Exp Path* 1998;79:255-65.
11. McDonald NQ, Hendrickson WA. A structural superfamily of growth factors containing a cystine knot motif. *Cell* 1993;73:421-4.
12. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. *Science* 1989;246:1306-9.
13. Tischer E, Gospodarowicz D, Mitchell R, Silva M, Schilling J, Lau K, et al. Vascular endothelial growth factor: a new member of the platelet-derived growth factor gene family. *Biochem Biophys Res Commun* 1989;165:1198-206.
14. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. *Mol Endocrinol* 1991;5:1806-14.
15. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. *J Biol Chem* 1991;266:11947-54.
16. Poltorak Z, Cohen T, Sivan R, Kandelis Y, Spira G, Vlodavsky I, et al. VEGF₁₄₅, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. *J Biol Chem* 1997;272:7151-8.
17. Maglione D, Guerriero V, Viglietto G, Ferraro M, Aprelikova A, Alitalo K, et al. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. *Oncogene* 1993;8:925-31.
18. Cao Y, Ji WR, Qi P, Rosin A, Cao YY. Placenta growth factor: identification and characterization of a novel isoform generated by RNA alternative splicing. *Biochem Biophys Res Commun* 1997;235:493-8.
19. Grimmond S, Lagercrantz J, Drinkwater C, Silins G, Townson S, Pollock P, et al. Cloning and characterization of a novel human gene related to vascular endothelial growth factor. *Genome Res* 1996;6:124-31.
20. Olofsson B, Pajusola K, von Euler G, Chilov D, Alitalo K, Eriksson U. Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform. *J Biol Chem* 1996;271:19310-17.
21. Baldwin ME, Roufail S, Halford MM, Alitalo K, Stacker SA, Achen MG. Multiple forms of mouse vascular endothelial growth factor-D are generated by RNA splicing and proteolysis. *J Biol Chem* 2001;276:44307-14.
22. Risau W. Mechanisms of angiogenesis. *Nature* 1997;386:671-4.
23. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. *Nature* 2000;407:242-8.
24. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. *Circ Res* 1999;85:221-8.
25. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. *Nat Med* 2001;7:1194-201.
26. Carmeliet P, Ferreira V, Breier G, Pollofeyt S, Kieckens L, Gertenstein M, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. *Nature* 1996;380:435-9.
27. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. *Nature* 1996;380:439-43.

28. Gerber H-P, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangel L et al. VEGF is required for growth and survival in neonatal mice. *Development* 1999;126:1149-59.
29. Ferrara N, Chen H, Davis-Smyth T, Gerber HP, Nguyen TN, Peers D, et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. *Nat Med* 1998;4:336-40.
30. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. *Nat Med* 1995;1:1024-8.
31. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. *Development* 1998;125:1591-8.
32. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, et al. Failure of blood-island formation and vasculogenesis in *flt-1*-deficient mice. *Nature* 1995;376:62-6.
33. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the *Flt*-receptor tyrosine kinase in regulating the assembly of vascular endothelium. *Nature* 1995;376:66-70.
34. Fong GH, Zhang L, Bryce DM, Peng J. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in *flt-1* knock-out mice. *Development* 1999;126:3015-25.
35. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. *Flt-1* lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. *Proc Natl Acad Sci USA* 1998;95:9349-54.
36. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. *J Biol Chem* 1992;267:26031-7.
37. Carmeliet P, Ng YS, Nuyens D, Theilmeier G, Brusselmans K, Cornelissen I, et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF₁₆₄ and VEGF₁₈₈. *Nat Med* 1999;5:495-502.
38. Neufeld G, Cohen T, Shraga N, Lange T, Kessler O, Herzog Y. The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. *Trends Cardiovasc Med* 2002;12:13-9.
39. Soker S, Fidler IJ, Neufeld G, Klagsburn M. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumour cells that bind VEGF₁₆₅ via its exon 7-encoded domain. *J Biol Chem* 1996;271:5761-67.
40. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsburn M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. *Cell* 1998;92:735-45.
41. Gluzman-Poltorak Z, Cohen T, Herzog Y, Neufeld G. Neuropilin-2 and neuropilin-1 are receptors for the 165-amino acid form of vascular endothelial growth factor (VEGF) and of placenta growth factor-2, but only neuropilin-2 functions as a receptor for the 145- amino acid form of VEGF. *J Biol Chem* 2000; 275:18040-5.
42. Kitsukawa T, Shimono A, Kawakami A, Kondoh H, Fujisawa H. Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. *Development* 1995; 121:4309-18.
43. Kawasaki T, Kitsukawa T, Bekku Y, Matsuda Y, Sanbo M, Yagi T, et al. A requirement for neuropilin-1 in embryonic vessel formation. *Development* 1999;126:4895-902.
44. Takashima S, Kitakaze M, Asakura M, Asanuma H, Sanada S, Tashiro F, et al. Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. *Proc Natl Acad Sci USA* 2002;99:3657-62.
45. Springer ML, Chen AS, Kraft PE, Bednarski M, Blau HM. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. *Mol Cell* 1998;2:549-58.
46. Detmar M, Brown LF, Schon MP, Elicker BM, Velasco P, Richard L, et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. *J Invest Dermatol* 1998;111:1-6.
47. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. *Nat Med* 2000;6:460-3.
48. Adams RH, Wilkinson GA, Weiss C, Diella F, Gale NW, Deutsch U, et al. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. *Genes Dev* 1999;13:295-306.
49. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival *in vivo*. *Proc Natl Acad Sci USA* 2002;99:11205-10.
50. Thurston G. Role of Angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. *Cell Tissue Res* 2003;314:61-8.
51. Olofsson B, Pajusola K, Kaipainen A, von Euler G, Joukov V, Saksela O, et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. *Proc Natl Acad Sci USA* 1996; 93:2576-81.
52. Li X, Aase K, Li H, von Euler G, Eriksson U. Isoform-specific expression of VEGF-B in nor-

- mal tissues and tumors. *Growth Factors* 2001; 19:49–59.
53. Makinen T, Olofsson B, Karpanen T, Hellman U, Soker S, Klagsbrun M, et al. Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. *J Biol Chem* 1999;274:21217–22.
 54. Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. *Proc Natl Acad Sci USA* 1998;95:11709–14.
 55. Bhardwaj S, Roy H, Gruchala M, Viita H, Kholova I, Kokina I, et al. Angiogenic responses of vascular endothelial growth factors in periaDVentitial tissue. *Hum Gene Ther* 2003;14:1451–562.
 56. Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, et al. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. *Circ Res* 2003;92:1098–106.
 57. Bellomo D, Headrick JP, Silins GU, Paterson CA, Thomas PS, Gartside M, et al. Mice lacking the vascular endothelial growth factor-B gene (*Vegfb*) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. *Circ Res* 2000;86:E29–E35.
 58. Maglione D, Guerriero V, Viglietto G, Delli Bovi P, Persico MG. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. *Proc Natl Acad Sci USA* 1991;88:9267–71.
 59. Persico MG, Vincenti V, DiPalma T. Structure, expression and receptor-binding properties of placenta growth factor (PlGF). *Curr Top Microbiol Immunol* 1999;237:31–40.
 60. Park JE, Chen HH, Winer J, Houck KA, Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. *J Biol Chem* 1994;269:25646–54.
 61. Migdal M, Huppertz B, Tessler S, Comforti A, Shibuya M, Reich R et al. Neuropilin-1 is a placenta growth factor-2 receptor. *J Biol Chem* 1998;273:22272–8.
 62. Gluzman-Poltorak Z, Cohen T, Herzog Y, Neufeld G. Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165. *J Biol Chem* 2000;275:18040–5.
 63. DiSalvo J, Bayne ML, Conn G, Kwok PW, Trivedi PG, Soderman DD, et al. Purification and characterization of a naturally occurring vascular endothelial growth factor.placenta growth factor heterodimer. *J Biol Chem* 1995;270:7717–23.
 64. Eriksson A, Cao R, Pawliuk R, Berg SM, Tsang M, Zhou D, et al. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. *Cancer Cell* 2002;1:99–108.
 65. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernelle V, De Mol M, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. *Nat Med* 2001;7:575–83.
 66. Odorisio T, Schietroma C, Zaccaria ML, Cianfarani F, Tiverson C, Tatangelo L, et al. Mice over-expressing placenta growth factor exhibit increased vascularization and vessel permeability. *J Cell Sci* 2002;115:2559–67.
 67. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. *Nat Med* 2002;8: 831–40.
 68. Pipp F, Heil M, Issbrucker K, Ziegelhoeffer T, Martin S, van den Heuvel J, et al. VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence for a monocyte-mediated mechanism. *Circ Res* 2003;92:378–85.
 69. Scholz D, Elsaesser H, Sauer A, Friedrich C, Luttun A, Carmeliet P, et al. Bone marrow transplantation abolishes inhibition of arteriogenesis in placenta growth factor (PlGF) $-/-$ mice. *J Mol Cell Cardiol* 2003;35:177–84.
 70. Clauss M, Weich H, Breier G, Knies U, Röckl W, Waltenberger J, et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. *J Biol Chem* 1996;271:17629–34.
 71. Folkman J. Tumor angiogenesis: therapeutic implications. *N Engl J Med* 1971;285:1182–6.
 72. Ferrara N. Timeline: VEGF and the quest for tumour angiogenesis factors. *Nat Rev Cancer* 2002;2:795–803.
 73. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. *Nature* 2000;407:249–57.
 74. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. *J Clin Oncol* 2002;20: 4368–80.
 75. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. *Curr Top Microbiol Immunol* 1999;237:97–132.
 76. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in

- tumors: frequency of cancer cells in contact with flowing blood. *Proc Natl Acad Sci USA* 2000; 97:14608-13.
77. Hendrix MJC, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. *Nat Rev Cancer* 2003; 3:411-21.
 78. Borgström P, Bourdon MA, Hillan KJ, Sriramaraio P, Ferrara N. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors *in vivo*. *Prostate* 1998;35:1-10.
 79. Borgstrom P, Gold DP, Hillan KJ, Ferrara N. Importance of VEGF for breast cancer angiogenesis *in vivo*: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. *Anticancer Res* 1999;19:4203-14.
 80. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth *in vivo*. *Nature* 1993;362: 841-4.
 81. Mattern J, Koomagi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. *Br J Cancer* 1996;73:931-4.
 82. Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. *Cancer Res* 1996;56: 2013-6.
 83. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. *Cancer Res* 1993;53:4727-35.
 84. Hartenbach EM, Olson TA, Goswitz JJ, Mohanraj D, Twiggs LB, Carson LF, et al. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. *Cancer Lett* 1997;121:169-75.
 85. Tokunaga T, Oshika Y, Abe Y, Ozeki Y, Sadahiro S, Kijima H, et al. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. *Br J Cancer* 1998;77: 998-1002.
 86. Berkman RA, Merrill MJ, Reinhold WC, Monacci WT, Saxena A, Clark WC, et al. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. *J Clin Invest* 1993;91:153-9.
 87. Toi M, Hoshina T, Takayanagi T, Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. *Jpn J Cancer Res* 1994;85:1045-9.
 88. Nomura M, Yamagishi S, Harada S, Yamashita T, Yamashita J, Yamamoto H. Placenta growth factor (PlGF) mRNA expression in brain tumors. *J Neurooncol* 1998;40:123-30.
 89. Hatva E, Bohling T, Jaaskelainen J, Persico MG, Haltia M, Alitalo K. Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. *Am J Pathol* 2004;148:763-75.
 90. Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, Trapasso F, et al. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. *Oncogene* 1995; 11:1569-79.
 91. Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. *J Thromb Haemost* 2003;1:1356-70.
 92. André T, Kotelevets L, Vaillant JC, Coudray AM, Weber L, Prévot S, et al. VEGF, VEGF-B, VEGF-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. *Int J Cancer* 2000;86: 174-81.
 93. Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, et al. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. *J Pathol* 2003;200:183-94.
 94. Harris AL. Hypoxia—a key regulatory factor in tumour growth. *Nat Rev Cancer* 2002;2:38-47.
 95. Minchenko A, Bauer T, Salceda S, Caro J. Hypoxic stimulation of vascular endothelial growth factor expression *in vitro* and *in vivo*. *Lab Invest* 1994;71:374-9.
 96. Shima DT, Adamis AP, Ferrara N, Yeo KT, Allende R, Folkman J, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. *Mol Med* 2004;1:182-93.
 97. Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. *J Biol Chem* 1995;270:19761-6.
 98. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. *Nature* 1992;359:843-5.

99. Semenza GL. Targeting HIF-1 for cancer therapy. *Nat Rev Cancer* 2003;3:721-32.
100. Ema M, Hirota K, Mimura J, Abe H, Yodoi J, Sogawa K, et al. Molecular mechanisms of transcription activation by HLF and HIF1 in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. *EMBO J* 1999;18:1905-14.
101. Bruick RK. Oxygen sensing in the hypoxic response pathway: regulation of the hypoxia-inducible transcription factor. *Genes Dev* 2003;17:2614-23.
102. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. *Nature* 1999;399:271-5.
103. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. *Science* 2001;294:1337-40.
104. Hirsila M, Koivunen P, Gunzler V, Kivirikko KI, Myllyharju J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. *J Biol Chem* 2003;278:30772-80.
105. Freedman SJ, Sun ZY, Poy F, Kung AL, Livingston DM, Wagner G, et al. Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. *Proc Natl Acad Sci USA* 2002;99:5367-72.
106. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. *Genes Dev* 2001;15:2675-86.
107. Hewitson KS, McNeill LA, Riordan MV, Tian YM, Bullock AN, Welford RW, et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. *J Biol Chem* 2004;277:26351-5.
108. Eferl R, Wagner EF. AP-1: a double edged sword in tumorigenesis. *Nat Rev Cancer* 2003;3:859-68.
109. Finkenzeller G, Marme D, Weich HA, Hug H. Platelet-derived growth factor-induced transcription of the vascular endothelial growth factor gene is mediated by protein kinase C. *Cancer Res* 1992;52:4821-3.
110. Garrido C, Saule S, Gospodarowicz D. Transcriptional regulation of vascular endothelial growth factor gene expression in ovarian bovine granulosa cells. *Growth Factors* 1993;8:109-17.
111. Frank S, Hubner G, Breier G, Longaker MT, Greenhalgh DG, Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. *J Biol Chem* 1995;270:12607-13.
112. Enholm B, Paavonen K, Ristimäki A, Kumar V, Gunji Y, Klefstrom J, et al. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. *Oncogene* 1997;14:2475-83.
113. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. *Cancer Res* 1995;55:4575-80.
114. Grugel S, Finkenzeller G, Weindel K, Barleon B, Marmé D. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. *J Biol Chem* 1995;270:25915-9.
115. Casanova ML, Larcher F, Casanova B, Murillas R, Fernández-Aceñero MJ, Villanueva C, et al. A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. *Cancer Res* 2002;62:3402-7.
116. Okada F, Rak JW, St.Croix B, Lieubeau B, Kaya M, Roncari L, et al. Impact of oncogenes in tumor angiogenesis: Mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. *Proc Natl Acad Sci USA* 1998;95:3609-14.
117. Kieser A, Weich HA, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. *Oncogene* 1994;9:963-9.
118. Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. *Cancer Res* 1995;55:6161-5.
119. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. *Genes Dev* 2000;14:34-44.
120. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Effect of p53 status on tumor response to antiangiogenic therapy. *Science* 2002;295:1526-28.
121. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. *Mol Biol Cell* 1993;4:1317-26.
122. Imaizumi T, Itaya H, Nasu S, Yoshida H, Matsubara Y, Fujimoto K, et al. Expression of vascular endothelial growth factor in human umbilical vein endothelial cells stimulated with interleukin-1alpha—an autocrine regulation of angiogenesis and inflammatory reactions. *Thromb Haemost* 2000;83:949-55.

123. Li J, Perrella MA, Tsai JC, Yet SF, Hsieh CM, Yoshizumi M, et al. Induction of vascular endothelial growth factor gene expression by interleukin-1 beta in rat aortic smooth muscle cells. *J Biol Chem* 1995;270:308–12.
124. Pai R, Szabo IL, Soreghan BA, Atay S, Kawanaka H, Tarnawski AS. PGE (2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. *Biochem Biophys Res Commun* 2001;286:923–28.
125. Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. *FEBS Lett* 1995;372:83–7.
126. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. *Cancer* 2000;89:2637–45.
127. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. *Cancer Res* 2000;60:1306–11.
128. Iñiguez MA, Rodriguez A, Volpert OV, Fresno M, Redondo JM. Cyclooxygenase-2: a therapeutic target in angiogenesis. *Trends Mol Med* 2003;9:73–8.
129. Green CJ, Lichtlen P, Huynh NT, Yanovsky M, Laderoute KR, Schaffner W, et al. Placenta growth factor gene expression is induced by hypoxia in fibroblasts: a central role for metal transcription factor-1. *Cancer Res* 2001;61:2696–703.
130. Zhang H, Palmer R, Gao X, Kreidberg J, Gerald W, Hsiao L, et al. Transcriptional activation of placental growth factor by the forkhead/winged helix transcription factor FoxD1. *Curr Biol* 2003;13:1625–9.
131. Failla CM, Odorisio T, Cianfarani F, Schietroma C, Puddu P, Zambruno G. Placenta growth factor is induced in human keratinocytes during wound healing. *J Invest Dermatol* 2000;115:388–95.
132. Hauser S, Weich H. A heparin-binding form of placenta growth factor (PlGF-2) is expressed in human umbilical vein endothelial cells and in placenta. *Growth Factors* 1993;9:259–68.
133. Yonekura H, Sakurai S, Liu X, Migita H, Wang H, Yamagishi S, et al. Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis. *J Biol Chem* 1999;274:35172–8.
134. Gollmer JC, Ladoux A., Gioanni J, Paquis P, Dubreuil A, Chatel M, et al. Expression of vascular endothelial growth factor-b in human astrocytoma. *Neuro-oncol* 2000;2:80–6.
135. Baldwin ME, Stacker SA, Achen MG. Molecular control of lymphangiogenesis. *Bioessays* 2002;24:1030–40.
136. Casley-Smith JR. The fine structure and functioning of tissue channels and lymphatics. *Lymphology* 1980;12:177–83.
137. Roitt I, Brostoff J, Male D. *Immunology*. 5th Edition. London: Mosby International, 1998.
138. Sabin F. On the origin and development of the lymphatic system from the veins and the development of lymph hearts and the thoracic duct in the pig. *Am J Anat* 1902;1:367–89.
139. Wigle JT, Oliver G. *Prox1* function is required for the development of the murine lymphatic system. *Cell* 1999;98:769–78.
140. Wigle JT, Harvey N, Detmar M, Lagutina I, Grosveld G, Gunn MD, et al. An essential role for *Prox1* in the induction of the lymphatic endothelial cell phenotype. *EMBO J* 2002;21:1505–13.
141. Oliver G. Lymphatic vasculature development. *Nat Rev Immunol* 2004;4:35–45.
142. Enholm B, Karpanen T, Jeltsch M, Kubo H, Stenback F, Prevo R, et al. Adenoviral expression of vascular endothelial growth factor-c induces lymphangiogenesis in the skin. *Circ Res* 2001;88:623–9.
143. Veikkola T, Jussila L, Mäkinen T, Karpanen T, Jeltsch M, Petrova TV, et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. *EMBO J* 2001;20:1223–31.
144. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. *Science* 1997;276:1423–5.
145. Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. *Nat Immunol* 2004;5:74–80.
146. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. *EMBO J* 1996;15:290–8.
147. Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk-1) and VEGF receptor 3 (Flt-4). *Proc Natl Acad Sci USA* 1998;95:548–53.
148. Baldwin ME, Catimel B, Nice EC, Roufail S, Hall NE, Stenvers KL, et al. The specificity of receptor binding by vascular endothelial growth factor-D is different in mouse and man. *J Biol Chem* 2001;276:19166–71.
149. Kaipainen A, Korhonen J, Mustonen T, van

- Hinsbergh VW, Fang GH, Dumont D, et al. Expression of the *fms*-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. *Proc Natl Acad Sci USA* 1995;92:3566–70.
150. Mäkinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC, et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. *EMBO J* 2001;20:4762–73.
 151. Dumont DJ, Jussila L, Taipale J, Lymboussaki A, Mustonen T, Pajusola K, et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. *Science* 1998;282:946–9.
 152. Karkkainen MJ, Saaristo A, Jussila L, Karila KA, Lawrence EC, Pajusola K, et al. A model for gene therapy of human hereditary lymphedema. *Proc Natl Acad Sci USA* 2001;98:12677–82.
 153. Yuan L, Moyon D, Pardanaud L, Bréant C, Karkkainen MJ, Alitalo K, et al. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. *Development* 2002;129:4797–806.
 154. Witzanbichler B, Asahara T, Murohara T, Silver M, Spyridopoulos I, Magner M, et al. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. *Am J Pathol* 1998;153:381–94.
 155. Marconcini L, Marchio S, Morbidelli L, Cartocci E, Albini A, Ziche M, et al. *c-fos*-induced growth factor/vascular endothelial growth factor D induces angiogenesis *in vivo* and *in vitro*. *Proc Natl Acad Sci USA* 1999;96:9671–6.
 156. Byzova TV, Goldman CK, Jankau J, Chen J, Cabrera G, Achen MG, et al. Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns *in vivo*. *Blood* 2002;99:4434–42.
 157. Cao Y, Linden P, Farnebo J, Cao R, Eriksson A, Kumar V, et al. Vascular endothelial growth factor C induces angiogenesis *in vivo*. *Proc Natl Acad Sci USA* 1998;95:14389–94.
 158. Skobe M, Hamberg LM, Hawighorst T, Schirner M, Wolf GL, Alitalo K, et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. *Am J Pathol* 2001;159:893–903.
 159. Stacker SA, Baldwin ME, Achen MG. The role of tumor lymphangiogenesis in metastatic spread. *FASEB J* 2002;16:922–34.
 160. Yanai Y, Furuhashi T, Kimura Y, Yamaguchi K, Yasoshima T, Mitaka T, et al. Vascular endothelial growth factor C promotes human gastric carcinoma lymph node metastasis in mice. *J Exp Clin Cancer Res* 2001;20:419–28.
 161. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. *EMBO J* 2001;20:672–82.
 162. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. *Nat Med* 2001;7:192–8.
 163. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Ylä-Herttuala S, Jäättelä M, et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. *Cancer Res* 2001;61:1786–90.
 164. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. *Nat Med* 2001;7:186–91.
 165. Kinoshita J, Kitamura K, Kabashima A, Saeki H, Tanaka S, Sugimachi K. Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. *Breast Cancer Res Treat* 2001;66:159–64.
 166. Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Tsukiyama A, Imabun S, et al. Clinicopathological significance of vascular endothelial growth factor-C in breast carcinoma with long-term follow-up. *Mod Pathol* 2003;16:309–14.
 167. Yonemura Y, Fushida S, Bando E, Kinoshita K, Miwa K, Endo Y, et al. Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer. *Eur J Cancer* 2001;37:918–23.
 168. Yokoyama Y, Charnock-Jones DS, Licence D, Yanaihara A, Hastings JM, Holland CM, et al. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. *Br J Cancer* 2003;88:237–44.
 169. Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Imabun S, Nakahara M, et al. Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up. *Clin Cancer Res* 2003;9:716–21.
 170. White JD, Hewett PW, Kosuge D, McCulloch T, Enholm BC, Carmichael J, et al. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. *Cancer Res* 2002;62:1669–75.
 171. Witte MH, Bernas MJ, Martin CP, Witte CL. Lymphangiogenesis and lymphangiodysplasia: From molecular to clinical lymphology. *Microsc Res Tech* 2001;55:122–45.
 172. Ferrell RE, Levinson KL, Esman JH, Kimak MA, Lawrence EC, Barmada MM et al. Hereditary lymphedema: evidence for linkage and genetic heterogeneity. *Hum Mol Genet* 1998;7:2073–8.
 173. Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K, Vikkula M. Congenital hereditary lymphedema caused by a mutation that inactivates

- VEGFR3 tyrosine kinase. *Am J Hum Genet* 2000;67:295–301.
174. Fang J, Dagenais SL, Erickson RP, Arlt MF, Glynn MW, Gorski JL, et al. Mutations in *FOXC2* (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. *Am J Hum Genet* 2000;67:1382–8.
 175. Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. *EMBO J* 1997;16:3898–911.
 176. Stacker SA, Stenvers K, Caesar C, Vitali A, Domagala T, Nice E, et al. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. *J Biol Chem* 1999;274:32127–36.
 177. Siegfried G, Basak A, Cromlish JA, Benjannet S, Marcinkiewicz J, Chretien M, et al. The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. *J Clin Invest* 2003;111:1723–32.
 178. McColl BK, Baldwin ME, Roufail S, Freeman C, Moritz RL, Simpson RJ, et al. Plasmin Activates the lymphangiogenic growth factors VEGF-C and VEGF-D. *J Exp Med* 2003;198:863–8.
 179. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. *Nat Rev Mol Cell Biol* 2002;3:753–66.
 180. Khatib AM, Siegfried G, Chretien M, Metrakos P, Seidah NG. Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. *Am J Pathol* 2002;160:1921–35.
 181. Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. *Genes Dev* 1995;9:794–807.
 182. Partanen TA, Arola J, Saaristo A, Jussila L, Ora A, Miettinen M, et al. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. *FASEB J* 2000;14:2087–96.
 183. Achen MG, Williams RA, Minekus MP, Thornton GE, Stenvers K, Rogers PAW, et al. Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis. *J Pathol* 2001;193:147–54.
 184. Bugge TH, Kombrinck KW, Xiao Q, Holmback K, Daugherty CC, Witte DP, et al. Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. *Blood* 1997;90:4522–31.
 185. Valtola R, Salven P, Heikkila P, Taipale J, Joensuu H, Rehn M, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. *Am J Pathol* 1999;154:1381–90.
 186. Ristimaki A, Narko K, Enholm B, Joukov V, Alitalo K. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. *J Biol Chem* 1998;273:8413–18.
 187. Su JL, Shih JY, Yen ML, Jeng YM, Chang CC, Hsieh CY, et al. Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. *Cancer Res* 2004;64:554–64.
 188. Pichiale P, Chavez JC, LaManna JC. Hypoxic regulation of angiopoietin-2 expression in endothelial cells. *J Biol Chem* 2003; Epub ahead of print.
 189. Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. *Dev Cell* 2002;3:411–23.
 190. Hida T, Yatabe Y, Achiwa H, Murmatsu H, Kozaki K, Nakamura S, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. *Cancer Res* 1998;58:3761–4.
 191. Orlandini M, Marconcini L, Ferruzzi R, Oliviero S. Identification of a *c-fos*-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. *Proc Natl Acad Sci USA* 1996;93:11675–80.
 192. Jenkins NA, Woollatt E, Crawford J, Gilbert DJ, Baldwin ME, Sutherland GR, et al. Mapping of the gene for vascular endothelial growth factor-D in mouse and man to the X chromosome. *Chromosome Res* 1997;5:502–5.
 193. Rocchigiani M, Lestingi M, Luddi A, Orlandini M, Franco B, Rossi E, et al. Human *FIGF*: cloning, gene structure, and mapping to chromosome Xp22.1 between the *PIGA* and the *GRPR* genes. *Genomics* 1998;47:207–16.
 194. Debinski W, Slagle-Webb B, Achen MG, Stacker SA, Tulchinsky E, Gillespie GY, et al. VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiforme. *Mol Med* 2001;7:598–608.
 195. Wheelock MJ, Johnson KR. Cadherins as modulators of cellular phenotype. *Ann Rev Cell Dev Biol* 2003;19:207–35.
 196. Orlandini M, Oliviero S. In fibroblasts *Vegf-D* expression is induced by cell-cell contact mediated by cadherin-11. *J Biol Chem* 2001;276:6576–81.
 197. Orlandini M, Semboloni S, Oliviero S. Beta-catenin inversely regulates vascular endothelial growth factor-D mRNA stability. *J Biol Chem* 2003; 278:44650–6.